LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Clinical trials for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG explained in plain language.
Never miss a new study
Get alerted when new LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG trials appear
Sign up with your email to follow new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare lung cancer: immunotherapy plus chemo shows promise
Disease control OngoingThis study is for people with a rare and advanced type of lung cancer called large-cell neuroendocrine carcinoma. It tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help patients live longer and control the cancer better. About 67 participant…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Radioactive drug targets tough lung cancers in early trial
Disease control OngoingThis early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine carcinoma of the lung whose cancer has progressed after platinum-based chemotherapy. The main goals are to check safety, find the best dose, and s…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE1 • Sponsor: Abdera Therapeutics Inc. • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New hope for tough lung cancers: targeted pill shows promise in early trial
Disease control OngoingThis study tests a pill called abemaciclib in people with specific lung cancers (small cell, large cell neuroendocrine, and related types) that have stopped responding to chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. 14 participants will recei…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
Engineered immune cells take aim at tough lung cancer
Disease control OngoingThis early-stage trial tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a specific marker (DLL3). The study includes about 41 adults with advanced small cell lung cancer o…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated May 04, 2026 16:31 UTC